MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




FDA Agrees to Review Insulin Inhalation Powder, Afrezza

Approval decision slated for April 2014 (October 30)

The FDA has acknowledged the resubmission of a New Drug Application (NDA) for Afrezza (insulin human [rDNA origin]) inhalation powder (Mannkind Corporation).

The agency considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011. The user fee goal date is April 15, 2014.

Afrezza is a rapid-acting mealtime insulin therapy in late-stage clinical investigation for the treatment of adult patients with type-1 and type-2 diabetes mellitus for the control of hyperglycemia. It is a drug–device combination product, consisting of Afrezza inhalation powder (pre-metered into single-use cartridges) and the Afrezza inhaler.

Source: Mannkind Corp.; October 30, 2013.

More stories